1. Home
  2. PRAX vs MTH Comparison

PRAX vs MTH Comparison

Compare PRAX & MTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$305.51

Market Cap

7.1B

Sector

Health Care

ML Signal

HOLD

Logo Meritage Homes Corporation

MTH

Meritage Homes Corporation

HOLD

Current Price

$72.30

Market Cap

5.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRAX
MTH
Founded
2015
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
5.7B
IPO Year
2020
1997

Fundamental Metrics

Financial Performance
Metric
PRAX
MTH
Price
$305.51
$72.30
Analyst Decision
Strong Buy
Buy
Analyst Count
15
8
Target Price
$572.13
$77.63
AVG Volume (30 Days)
329.6K
886.3K
Earning Date
05-08-2026
04-22-2026
Dividend Yield
N/A
2.87%
EPS Growth
N/A
N/A
EPS
N/A
2.18
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7,758.26
$9.81
P/E Ratio
N/A
$85.61
Revenue Growth
N/A
N/A
52 Week Low
$37.25
$58.03
52 Week High
$366.52
$85.38

Technical Indicators

Market Signals
Indicator
PRAX
MTH
Relative Strength Index (RSI) 46.51 42.86
Support Level $284.87 $64.62
Resistance Level $331.21 $71.13
Average True Range (ATR) 16.88 3.01
MACD -2.16 -0.49
Stochastic Oscillator 34.34 20.44

Price Performance

Historical Comparison
PRAX
MTH

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

About MTH Meritage Homes Corporation

Meritage Homes Corp is engaged as a designer and builder of single-family attached and detached homes. It has operations in three regions: West, Central, and East, comprising twelve states: Arizona, California, Colorado, Utah, Tennessee, Texas, Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina. The company operates with two principal business segments: homebuilding and financial services. The homebuilding segments are engaged in the business of acquiring and developing land, constructing homes, marketing and selling those homes, and providing warranty and customer services, and the financial services segment offers title and escrow, mortgage, and insurance services. The company generates key revenue from the Homebuilding segment.

Share on Social Networks: